Dossier - 24/05/2019 Tumour metastasis Cancer is usually not curable when metastases have formed in the body. Metastases are often resistant to drugs that have successfully eliminated the primary tumour. The basic features of the complex process of metastasis are now known, but many details still remain elusive. Intensive research activities are focusing on new therapeutic concepts aimed at developing effective anti-metastatic therapies.https://www.gesundheitsindustrie-bw.de/en/article/dossier/tumour-metastasis
Article - 16/04/2019 Tumour monitoring using liquid biopsy Liquid biopsy, the analysis of cancer biomarkers and circulating tumour cells in body fluids such as blood, is revolutionising the diagnosis and monitoring of cancer. It has also been possible to expand circulating tumour cells from the blood under laboratory conditions. It is expected that in the future, liquid biopsy will be able to precisely characterise tumour cells at every stage of a cancer.https://www.gesundheitsindustrie-bw.de/en/article/news/tumour-monitoring-using-liquid-biopsy
Event - 02/07/2019 Meet & Match: Precision Medicine – Research, Diagnostics & Therapy Stuttgart, Registration deadline: 01/07/2019, Meet & Match https://www.gesundheitsindustrie-bw.de/en/event/meet-match-precision-medicine
Article - 22/03/2019 Personalised therapies for treating metastasing breast cancer Breast cancer is characterised by broad genetic diversity. Successful treatment is made even more difficult by the fact that, in advanced breast cancer, the properties of metastases often differ significantly from the primary tumour. The Heidelberg CATCH study is now collecting genetic profiles from patients' metastasis tissue samples, which can be used to tailor therapy to individual requirements.https://www.gesundheitsindustrie-bw.de/en/article/news/personalisierte-therapieansaetze-bei-metastasiertem-brustkrebs
Article - 13/11/2018 Rapid medical test for at-home use For quite a number of illnesses, patients need to have the concentrations of the medications they are taking and their blood metabolites checked on a regular basis, which can make life rather difficult. Researchers at the Max Planck Institute for Medical Research in Heidelberg have now developed a test based on the firefly enzyme luciferase. This enzyme can be used to quickly and cheaply measure parameters of interest.https://www.gesundheitsindustrie-bw.de/en/article/news/rapid-medical-test-for-at-home-use
Dossier - 28/08/2018 With molecular diagnostics to biomarker-based personalised therapy Diagnosing suitable biomarkers is a prerequisite for tailoring personalised therapies to patient heterogeneity. Genetic tests and genome sequencing play a key role in these diagnoses. Up until now, personalised therapy has achieved the greatest success in the field of oncology. However, personalised treatments are also gaining in importance for treating other diseases.https://www.gesundheitsindustrie-bw.de/en/article/dossier/with-molecular-diagnostics-to-biomarker-based-personalised-therapy
Article - 08/08/2018 Ludolph: diagnosing and treating neurodegenerative disorders Ulm has long been a world leader in diagnosing and treating rare neurological disorders, notably amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD) and Huntington's disease (HD). We spoke with Professor Albert C. Ludolph, spokesperson for the Ulm DZNE site, medical director of the Clinic for Neurology at the RKU (University and Rehabilitation Clinics of Ulm) and world-renowned ALS researcher.https://www.gesundheitsindustrie-bw.de/en/article/news/ludolph-diagnosing-and-treating-neurodegenerative-disorders
Press release - 04/10/2017 Immatics Receives $58 Million in Financing to Develop T-Cell Receptor Based Immunotherapies Tuebingen, Germany and Houston, Texas, October 4, 2017 – Immatics, a leading company in the field of cancer immunotherapy, today announced the completion of its Series E financing, raising $58 million.https://www.gesundheitsindustrie-bw.de/en/article/press-release/immatics-receives-58-million-in-financing-to-develop-t-cell-receptor-based-immunotherapies
Press release - 05/09/2017 Cell marking opens up a window into the body A new and particularly reliable method for marking cells can simplify research into diseases such as myocardial infarction, diabetes or Alzheimer's and reduce the use of test animals: Scientists from the University of Tübingen have developed a method by which they can target specific cell types in mice and monitor their behavior using positron emission tomography (PET). PET-based cell tracking allows scientists to observe complex life…https://www.gesundheitsindustrie-bw.de/en/article/press-release/cell-marking-opens-up-a-window-into-the-body
Article - 04/07/2017 Ruxolitinib – successful graft-versus-host disease treatment Graft-versus-host disease is a serious complication in leukaemia patients who have been given a blood stem cell transplant from a genetically different person. Prof. Dr. Nikolas von Bubnoff and Prof. Dr. Robert Zeiser from the Department of Haematology, Oncology and Stem Cell Transplantation at Freiburg University Medical Centre initiated a Germany-wide study to show that an active substance called ruxolitinib has a promising therapeutic effect.…https://www.gesundheitsindustrie-bw.de/en/article/news/ruxolitinib-successful-graft-versus-host-disease-treatment
Event - 27/11/2017 Meet & Match: Strategies for Drug Discovery: Simulation – Screening – Repurposing Strasbourg, France, Registration deadline: 23/11/2017, Meet & Match https://www.gesundheitsindustrie-bw.de/en/event/drugdiscovery
Press release - 24/05/2017 High-Tech Gründerfonds (HTGF) invests in Reutlingen-based SIGNATOPE GmbH – Safe medications thanks to new test procedures High-Tech Gründerfonds is investing EUR 600,000 in Reutlingen-based SIGNATOPE GmbH. SIGNATOPE will use the funds to advance the development of its unique biomarker assay system, that has been established to support pharmaceutical research. The technology is based on special antibodies and allows the early detection of possible side effects during the drug development process. Thereby, the need for animal testing will be reduced while the drug…https://www.gesundheitsindustrie-bw.de/en/article/press-release/high-tech-gruenderfonds-htgf-invests-in-reutlingen-based-signatope-gmbh-safe-medications-thanks-to-new-test-procedures
Article - 18/05/2017 ImmuStick – novel rapid test for identifying disease pathogens In some situations such as in the food and pharmaceutical industries or hospitals, a test to identify disease pathogens can be vital. At present, such tests are relatively time-consuming and can take hours or even days to produce results, depending on the pathogen. Scientists from the Fraunhofer Institute for Interfacial Engineering and Biotechnology IGB in Stuttgart are currently developing a rapid test called ImmuStick which is as easy to use…https://www.gesundheitsindustrie-bw.de/en/article/news/immustick-novel-rapid-test-for-identifying-disease-pathogens
Article - 31/03/2017 Bosch to enter the medical technology sector – start-up culture meets proven expertise Many of us have known the Bosch Group mainly as a technology company that is active in the automotive sector. Now, the multinational company is opening up a whole new field of business and is entering the medical technology market with a new subsidiary. Bosch Healthcare Solutions GmbH, which is headquartered in the city of Waiblingen, has developed an innovative breath analysis device that allows asthmatics to measure the severity of airway…https://www.gesundheitsindustrie-bw.de/en/article/news/bosch-to-enter-the-medical-technology-sector-start-up-culture-meets-proven-expertise
Article - 27/02/2017 Michael Baumann – the new man at the helm of the DKFZ On 1st November 2016, Professor Michael Baumann, a radiation oncologist from Dresden, became the new chairman and scientific director of the German Cancer Research Center in Heidelberg. Michael Baumann has the perfect background when it comes to combining basic and applied cancer research. This enables scientific findings to be used more quickly and effectively for preventing, diagnosing and treating cancer, and patients’ individual needs to be…https://www.gesundheitsindustrie-bw.de/en/article/news/michael-baumann-the-new-man-at-the-helm-of-the-dkfz
Article - 21/12/2016 For all types of tests: Signatope’s biomarker assays Signatope is a new biotech company that has been offering innovative biomarker assays for application in drug discovery since August 2016. The company’s assays can be used in all phases of drug development to detect potential adverse drug effects on the kidneys, liver and other organs in any species whatsoever using minute amounts of sample.https://www.gesundheitsindustrie-bw.de/en/article/news/for-all-types-of-tests-signatopes-biomarker-assays
Article - 13/12/2016 Smart sensor technology from Ulm can do more than just breath analysis Detecting disease-specific molecules in human breath is technically feasible, but time-consuming and rather costly. "µbreath" could soon change this. The breath gas analysis device has all the necessary requirements for commercial success in the healthcare sector: it is compact, accurate, highly sensitive and fast. The chemist who developed µbreath, Prof. Boris Mizaikoff from Ulm University, and his partners are hoping to start…https://www.gesundheitsindustrie-bw.de/en/article/news/smart-sensor-technology-from-ulm-can-do-more-than-just-breath-analysis
Article - 12/09/2016 New target for the therapy of hepatocellular carcinoma discovered Hepatocellular carcinoma is the second most common cause of cancer deaths worldwide. If the tumour is at an advanced stage, doctors have few treatment options. Researchers led by Prof. Dr. Lars Zender from the University of Tübingen have now identified one of the cancer's Achilles' heels, namely, the interaction between C-MYC and AURKA proteins, which can be destabilised with a drug, thus killing cancer cells. https://www.gesundheitsindustrie-bw.de/en/article/news/new-target-for-the-therapy-of-hepatocellular-carcinoma-discovered
Press release - 07/07/2016 DiagNeeds: translating clinical requirements into new products (Lake Constance/Stuttgart) – BioLAGO e.V. and BIOPRO Baden-Württemberg GmbH are working together on the “DiagNeeds” project to bring hospitals and medical professionals closer to diagnostics providers in order to facilitate the development of new diagnostic procedures. There will be special focus on topics that are currently of major interest in the field of diagnostics, including liquid biopsies, companion diagnostics, point-of-care diagnostics…https://www.gesundheitsindustrie-bw.de/en/article/press-release/diagneeds-klinik-bedarfe-in-neue-produkte-uebersetzen
Article - 25/04/2016 Pancreatic cancer and its resistance to therapy Pancreatic tumours are among the cancers with the worst prognosis. In many cases they are resistant to treatment. Prof. Dr. Andreas Trumpp and his colleagues from the DKFZ and the Heidelberg Institute for Stem Cell Technology and Experimental Medicine HI-STEM have discovered that the reason why some pancreatic tumours are so resistant to treatment is down to larger quantities of the enzyme CYP3A5 in subtypes of pancreatic cancer. Molecular…https://www.gesundheitsindustrie-bw.de/en/article/news/pancreatic-cancer-and-its-resistance-to-therapy
Article - 28/01/2016 Crowdsourcing initiative to tackle Alzheimer’s The BioMed X Innovation Center and the biopharmaceutical company AbbVie Deutschland GmbH & Co. KG have used crowdsourcing to set up a team of scientists from renowned international institutions to investigate new options for treating Alzheimer’s disease. The team are looking for targets in the metabolism of tau proteins and its pathological modifications that can be used to develop drugs to treat Alzheimer’s disease.https://www.gesundheitsindustrie-bw.de/en/article/news/crowdsourcing-initiative-to-tackle-alzheimers
Article - 21/01/2016 Genome research as information research DNA sequencing has become indispensable in modern science. Innovative advances that will bring about changes in the life sciences and medicine are due to rapid developments in genome analysis technologies. In the interview below, Peter Pohl, CEO and co-founder of GATC Biotech AG, explains why DNA sequencing will become even more important in future. https://www.gesundheitsindustrie-bw.de/en/article/news/genome-research-as-information-research
Article - 28/09/2015 Breast cancer: a few millilitres of urine to diagnose the disease early It would be phenomenal news if it turned out that breast cancer could be detected by way of urine samples. Treating physicians would be able to use conspicuous test results to begin further examinations as quickly as possible along with therapy if necessary. Prof. Dr. Elmar Stickeler and his team from the Freiburg University Medical Centre have developed a method that identifies the composition of microRNAs in urine. They were able to predict…https://www.gesundheitsindustrie-bw.de/en/article/news/breast-cancer-a-few-millilitres-of-urine-to-diagnose-the-disease-early
Article - 21/09/2015 Hans-Peter Deigner: "Optimisation of lateral flow assays using nanoparticles." Nanoparticles are already used in many materials and areas, ranging from textiles to scientific and medical research. The global scientific community is keenly interested in nanoparticle research and Prof. Dr. Hans-Peter Deigner, professor in the Faculty of Medical and Life Sciences at Furtwangen University of Applied Sciences (HFU) is no exception. Deigner works on optimising nanoparticles for application in lateral flow assays. As well as…https://www.gesundheitsindustrie-bw.de/en/article/news/hans-peter-deigner-optimisation-of-lateral-flow-assays-using-nanoparticles
Article - 11/05/2015 Lung cancer: MTSS1 is a putative marker of tumour progression and metastatic disease Lung cancer is one of the most common malignant diseases and one of the leading causes of cancer-related deaths worldwide. 90% of all lung cancer cases in men and 80% in women are due to long-term exposure to tobacco smoke. In Germany, around 140 new cases are diagnosed every day, and 50,000 people die of lung cancer every year. PD Dr. Gian Kayser, senior consultant in the Department of Clinical Pathology at Freiburg University Medical Centre,…https://www.gesundheitsindustrie-bw.de/en/article/news/lung-cancer-mtss1-is-a-putative-marker-of-tumour-progression-and-metastatic-disease